ALNY Quote, Financials, Valuation and Earnings

Blueprint Medicines has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of 0.33%. Alnylam Pharmaceuticals's return on equity of -- beat Blueprint Medicines's return on equity of -49.13%.

Alnylam Pharmaceuticals has a consensus price target of $330.77, signalling upside risk potential of 2.47%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -1.87%. Given that Alnylam Pharmaceuticals has higher upside potential than Blueprint Medicines, analysts believe Alnylam Pharmaceuticals is more attractive than Blueprint Medicines.

Alnylam Pharmaceuticals has a beta of 0.226, which suggesting that the stock is 77.386% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.564%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are larger than Blueprint Medicines quarterly revenues of $149.4M. Alnylam Pharmaceuticals's net income of -$57.5M is lower than Blueprint Medicines's net income of $496K. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 17.67x versus 14.74x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

AVITA Medical has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of -74.86%. Alnylam Pharmaceuticals's return on equity of -- beat AVITA Medical's return on equity of -415.55%.

Alnylam Pharmaceuticals has a consensus price target of $330.77, signalling upside risk potential of 2.47%. On the other hand AVITA Medical has an analysts' consensus of $16.95 which suggests that it could grow by 217.12%. Given that AVITA Medical has higher upside potential than Alnylam Pharmaceuticals, analysts believe AVITA Medical is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.226, which suggesting that the stock is 77.386% less volatile than S&P 500. In comparison AVITA Medical has a beta of 1.518, suggesting its more volatile than the S&P 500 by 51.797%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. AVITA Medical pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are larger than AVITA Medical quarterly revenues of $18.5M. Alnylam Pharmaceuticals's net income of -$57.5M is lower than AVITA Medical's net income of -$13.9M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while AVITA Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 17.67x versus 1.94x for AVITA Medical. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of 4.19%. Alnylam Pharmaceuticals's return on equity of -- beat TG Therapeutics's return on equity of 19.78%.

Alnylam Pharmaceuticals has a consensus price target of $330.77, signalling upside risk potential of 2.47%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 4.27%. Given that TG Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe TG Therapeutics is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.226, which suggesting that the stock is 77.386% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are larger than TG Therapeutics quarterly revenues of $120.9M. Alnylam Pharmaceuticals's net income of -$57.5M is lower than TG Therapeutics's net income of $5.1M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 161.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 17.67x versus 16.16x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of -6742.75%. Alnylam Pharmaceuticals's return on equity of -- beat Vir Biotechnology's return on equity of -45.02%.

Alnylam Pharmaceuticals has a consensus price target of $330.77, signalling upside risk potential of 2.47%. On the other hand Vir Biotechnology has an analysts' consensus of $17.63 which suggests that it could grow by 225.79%. Given that Vir Biotechnology has higher upside potential than Alnylam Pharmaceuticals, analysts believe Vir Biotechnology is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.226, which suggesting that the stock is 77.386% less volatile than S&P 500. In comparison Vir Biotechnology has a beta of 1.224, suggesting its more volatile than the S&P 500 by 22.375%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Vir Biotechnology pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are larger than Vir Biotechnology quarterly revenues of $1.8M. Alnylam Pharmaceuticals's net income of -$57.5M is higher than Vir Biotechnology's net income of -$121M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Vir Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 17.67x versus 51.74x for Vir Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.